Polymers based on polyarylene siloxanes and freeradical-polymerizable
monomers
    32.
    发明授权
    Polymers based on polyarylene siloxanes and freeradical-polymerizable monomers 失效
    基于聚亚芳基硅氧烷和可自由基聚合单体的聚合物

    公开(公告)号:US5633332A

    公开(公告)日:1997-05-27

    申请号:US428066

    申请日:1995-04-26

    摘要: Polymers can be obtained by free-radical polymerization of monomers in the presence of a dissolved polysiloxane. The free-radical-polymerizable monomers used are at least one compound of the formula I ##STR1## where R.sup.1 and R.sup.2 are, independently of one another, hydrogen, COOH, C.sub.1 -C.sub.18 -alkyl, cyclohexyl, C.sub.1 -C.sub.4 -alkyl-cyclohexyl, C.sub.6 -C.sub.10 -bicycloalkyl, C.sub.6 -C.sub.18 -tricycloalkyl,R.sup.3 is hydrogen or methyl,R.sup.4 is hydrogen, (C.sub.1 -C.sub.20)-alkyl, 2-hydroxypropyl, glycidyl,--[CH.sub.2 CH.sub.2 --O].sub.n H, having n=1 to 5,--[CH.sub.2 ].sub.m --OH, having m=3 to 18, in particular m=3 to 8,--[CH.sub.2 ].sub.2 O--[CO--(CH.sub.2).sub.5 ].sub.x OH, where x=a number from 1 to 3, or--[CH.sub.2 CHOHCH.sub.2 ]--O--(CO)R,where R is a C.sub.1 to C.sub.18 -alkyl radical.The polysiloxane used is at least one aromatic polyarylene siloxane of the formula III ##STR2## where R.sup.9 and R.sup.10 are, independently of one another, a C.sub.1 -C.sub.12 -alkyl radical, a C.sub.6 -C.sub.14 -aryl radical, or an unsubstituted or substituted vinyl radical, andR.sup.11, R.sup.12, R.sup.13 and R.sup.14 are, independently of one another, hydrogen, a C.sub.1 -C.sub.3 -alkyl radical or a substituted or unsubstituted C.sub.6 -C.sub.14 -aryl radical and--X-- is a group --C(CH.sub.3).sub.2 --, --C(CF.sub.3).sub.2 --, --S--, --SO.sub.2 --, --CH.sub.2 -- or a cyclohexylidene group, or a single chemical bond and M is equal to 0 or 1 and N is a number from 2 to 500, in particular from 3 to 200.

    摘要翻译: PCT No.PCT / EP93 / 02854 Sec。 371日期1995年04月26日 102(e)日期1995年4月26日PCT提交1993年10月15日PCT公布。 WO94 / 10218 PCT公开号 日期1994年5月11日聚合物可以通过在溶解的聚硅氧烷存在下单体的自由基聚合获得。 使用的可自由基聚合的单体是至少一种式I(I)的化合物,其中R 1和R 2彼此独立地为氢,COOH,C 1 -C 18 - 烷基,环己基,C 1 -C 4 - 烷基 - 环己基,C6-C10-双环烷基,C6-C18-三环烷基,R3是氢或甲基,R4是氢,(C1-C20) - 烷基,2-羟丙基,缩水甘油基, - [CH2CH2-O] m = 3至18,特别是m = 3至8, - [CH 2] 2 O- [CO-(CH 2)5] x OH,其中x = 1〜3,或 - [CH2CHOHCH2] -O-(CO)R,其中R为C1至C18-烷基。 所使用的聚硅氧烷是至少一种式III(III)的芳族聚亚芳基硅氧烷,其中R 9和R 10彼此独立地为C 1 -C 12 - 烷基,C 6 -C 14 - 芳基或未取代的 或取代的乙烯基,R11,R12,R13和R14彼此独立地为氢,C1-C3-烷基或取代或未取代的C6-C14 - 芳基,-X-为基团-C( CH 3)2 - , - C(CF 3)2 - , - S - , - SO 2 - , - CH 2 - 或亚环己基,或单一化学键,M等于0或1,N是2〜 500,特别是3到200。

    Multi-color labeling of different antigens in a biological system
    34.
    发明授权
    Multi-color labeling of different antigens in a biological system 失效
    生物系统中不同抗原的多色标记

    公开(公告)号:US4918000A

    公开(公告)日:1990-04-17

    申请号:US780958

    申请日:1985-09-27

    申请人: Walter Schubert

    发明人: Walter Schubert

    摘要: A method of multi-color labeling at least two antigens present in a tissue such as non-liquid tissue or body fluids, with the aid of different antibodies is improved by introducing between the labeling of the first antigen and the labeling of the second antigen, and between labeling of the second and that of any further antigen, at least once a treatment with a non-immune normal serum and optionally other agents blocking any binding sites remaining free in the tissue after a last-preceding labeling step.

    摘要翻译: 通过在第一抗原的标记和第二抗原的标记之间引入,借助于不同抗体,多色标记存在于组织中的至少两种抗原如非液体组织或体液的方法得到改善, 并且在第二个标记和任何另外的抗原的标记之间,至少一次用非免疫正常血清和任选的其它试剂阻止在最后一个标记步骤之后在组织中残留的结合位点。

    Apparatus and method for measurement of the reception time of a pulse
    35.
    发明授权
    Apparatus and method for measurement of the reception time of a pulse 有权
    用于测量脉冲的接收时间的装置和方法

    公开(公告)号:US08995577B2

    公开(公告)日:2015-03-31

    申请号:US12989009

    申请日:2009-04-14

    摘要: Apparatus for measurement of the reception time of a pulse in a receiving system, which contains at least one receiving channel with a non-linear transmission response, which receiving channel produces at its output a received signal, having a memory, in which the received signals of reference pulses with a predetermined different amplitude are available as reference signals with respect to a time scale, and having an evaluation device, which is connected to the receiving system and to the memory and compares a received signal with each reference signal with a variant time offset in order to determine that reference signal and that time offset for which the comparison discrepancy is a minimum, and outputs this time offset as the reception time with respect to the time scale.

    摘要翻译: 用于测量接收系统中的脉冲的接收时间的装置,其包含至少一个具有非线性传输响应的接收信道,该接收信道在其输出端产生具有存储器的接收信号,其中接收信号 具有预定不同振幅的参考脉冲可用作相对于时标的参考信号,并且具有连接到接收系统和存储器的评估装置,并将接收信号与每个参考信号与变量时间进行比较 偏移以便确定参考信号和比较差异最小的时间偏移量,并输出该时间偏移量作为相对于时间标度的接收时间。

    PHARMACEUTICAL COMPOSITION AND METHOD FOR IDENTIFYING A CANCEROUS AND/OR AN INFLAMMATORY DISEASE IN A PATIENT
    36.
    发明申请
    PHARMACEUTICAL COMPOSITION AND METHOD FOR IDENTIFYING A CANCEROUS AND/OR AN INFLAMMATORY DISEASE IN A PATIENT 审中-公开
    药物组合物和识别患者中的癌症和/或炎症疾病的方法

    公开(公告)号:US20110311443A1

    公开(公告)日:2011-12-22

    申请号:US13254103

    申请日:2010-03-01

    申请人: Walter Schubert

    发明人: Walter Schubert

    摘要: The invention relates to a method for treating a cancerous and/or an inflammatory disease in a patient, comprising internally administering to the patient an effective amount of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or CD29. The invention also relates to a pharmaceutical composition for the treatment of a cancerous and/or an inflammatory disease in a patient, a method for identifying a cancerous and/or an inflammatory disease in a patient, a method of identifying at least one candidate for development of anti-cancerous or anti-inflammatory agents, a use of an antibody for preparing a pharmaceutical preparation or medicament for the treatment of prostate cancer, a composition or kit comprising at least one antibody and/or at least one ligand, and a biochip.

    摘要翻译: 本发明涉及一种用于治疗患者的癌性和/或炎性疾病的方法,其包括向患者内部施用有效量的阻断至少一种蛋白质簇(CMP)或一组CMP的生物学活性的药物制剂 至少含有CD26和/或CD29。 本发明还涉及用于治疗患者中的癌性和/或炎性疾病的药物组合物,用于鉴定患者中的癌性和/或炎性疾病的方法,鉴定至少一种发育候选物的方法 抗癌剂或抗炎剂,抗体用于制备用于治疗前列腺癌的药物制剂或药物,包含至少一种抗体和/或至少一种配体的组合物或试剂盒以及生物芯片。

    Apparatus and Method for Measurement of the Reception Time of a Pulse
    37.
    发明申请
    Apparatus and Method for Measurement of the Reception Time of a Pulse 有权
    用于测量脉冲接收时间的装置和方法

    公开(公告)号:US20110038442A1

    公开(公告)日:2011-02-17

    申请号:US12989009

    申请日:2009-04-14

    IPC分类号: H04L27/06

    摘要: Apparatus for measurement of the reception time of a pulse in a receiving system, which contains at least one receiving channel with a non-linear transmission response, which receiving channel produces at its output a received signal, having a memory, in which the received signals of reference pulses with a predetermined different amplitude are available as reference signals with respect to a time scale, and having an evaluation device, which is connected to the receiving system and to the memory and compares a received signal with each reference signal with a variant time offset in order to determine that reference signal and that time offset for which the comparison discrepancy is a minimum, and outputs this time offset as the reception time with respect to the time scale.

    摘要翻译: 用于测量接收系统中的脉冲的接收时间的装置,其包含至少一个具有非线性传输响应的接收信道,该接收信道在其输出端产生具有存储器的接收信号,其中接收信号 具有预定不同振幅的参考脉冲可用作相对于时标的参考信号,并且具有连接到接收系统和存储器的评估装置,并将接收信号与每个参考信号与变量时间进行比较 偏移以便确定参考信号和比较差异最小的时间偏移量,并输出该时间偏移量作为相对于时间标度的接收时间。

    Process for identifying and enriching cell-specific target structures
    38.
    发明授权
    Process for identifying and enriching cell-specific target structures 失效
    识别和丰富细胞特异性靶结构的方法

    公开(公告)号:US06974675B2

    公开(公告)日:2005-12-13

    申请号:US09808225

    申请日:2001-03-14

    申请人: Walter Schubert

    发明人: Walter Schubert

    摘要: This invention relates to a process for identifying and enriching cell-specific target structures, in particular for the identification of cell-specific protein combination patterns on the surface of cells and for enriching such cells. The process comprises depositing a heterogeneous cell mixture one or plural surfaces with predefined structures causing cells with corresponding target structures to become bound to such surface(s), removing any non-binding cells of said cell mixture from said surface, identifying the cell-specific target structures responsible for the binding of the cells to said surface(s), selecting and enriching cells with identical cell-specific target structures on said surface(s), and biochemically characterizing the target structures.

    摘要翻译: 本发明涉及用于鉴定和富集细胞特异性靶结构的方法,特别是用于鉴定细胞表面上的细胞特异性蛋白质组合图案并富集这种细胞。 该方法包括用预定义的结构沉积一个或多个表面的异质细胞混合物,使得具有相应靶结构的细胞结合到这样的表面,从所述表面去除所述细胞混合物的任何非结合细胞,鉴定细胞特异性 负责细胞与所述表面结合的靶结构,在所述表面上选择和富集具有相同细胞特异性靶结构的细胞,以及生物化学表征靶结构。

    Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble Fc&ggr;RIII receptors
    39.
    发明授权
    Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble Fc&ggr;RIII receptors 失效
    使用可溶性FcγRIII受体在肌萎缩性侧索硬化患者中阻断细胞毒性活性的方法

    公开(公告)号:US06649165B2

    公开(公告)日:2003-11-18

    申请号:US09802305

    申请日:2001-03-08

    申请人: Walter Schubert

    发明人: Walter Schubert

    IPC分类号: A61K3817

    摘要: The present invention is directed to a method of blocking the cytotoxic activity of Fc&ggr;RIII receptor-positive immune cells in a patient with amyotrophic lateral sclerosis using an effective amount of soluble Fc&ggr;RIII receptors. The soluble Fc&ggr;RIII receptors of the invention are specific for immunoglobulin G of under-class 1 (IgG1) and/or 3 (IgG3).

    摘要翻译: 本发明涉及使用有效量的可溶性FcγRIII受体来阻断肌萎缩性侧索硬化患者中FcγAM受体阳性免疫细胞的细胞毒活性的方法。 本发明的可溶性FcγRIII受体对于低于1级(IgG1)和/或3(IgG3)的免疫球蛋白G是特异性的。

    Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V
    40.
    发明授权
    Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V 失效
    使用蛋白V阻断肌萎缩性侧索硬化患者的细胞毒活性的方法

    公开(公告)号:US06638515B2

    公开(公告)日:2003-10-28

    申请号:US09801414

    申请日:2001-03-08

    申请人: Walter Schubert

    发明人: Walter Schubert

    IPC分类号: A61K3574

    摘要: The present invention is directed to a method of blocking the cytotoxic activity of Fc&ggr;RIII receptor-positive immune cells in a patient with amyotrophic lateral sclerosis using protein V specific for IgG1 and/or IgG3. In one aspect of the invention, protein V blocks the binding of IgG1 and/or IgG3 to the Fc&ggr;RIII receptor, which inactivates the receptor, and destroys cellular forms containing the receptor.

    摘要翻译: 本发明涉及使用对IgG1和/或IgG3特异的蛋白质V来阻断肌萎缩性侧索硬化患者中FcγAM受体阳性免疫细胞的细胞毒性活性的方法。 在本发明的一个方面,蛋白质V阻断IgG1和/或IgG3与FcγRIII受体的结合,其使受体失活,并破坏含有受体的细胞形式。